Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00147056 · ClinicalTrials.gov registry record · NA

MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors

A NA study of Brain Tumor, sponsored by InSightec.

Active
Registry status
NA
Development phase
10
Enrollment target
2
Study locations

NCT00147056 is a NA study of Brain Tumor that is active but no longer recruiting, run by InSightec. The registered enrollment target is 10 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00147056, a NA study of Brain Tumor, is active but no longer recruiting, sponsored by InSightec.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system. We will collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its clinical efficacy.

Conditions Studied

Interventions

  • DEVICE ExAblate transcranial system

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston

Washington

  • Swedish Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2012-08
Est. Completion 2026-12
Phase NA

Sponsor

InSightec

38 total trials

What the Registry Record Tells You About NCT00147056

The ClinicalTrials.gov registry entry for NCT00147056 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (96% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which ExAblate transcranial system is the first listed.

NCT00147056 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Washington.

Frequently Asked Questions

What is clinical trial NCT00147056 about?

NCT00147056 is a clinical study titled "MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors". The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system. We will collect data to establish the basic safety of this type of treatment as the basis for later studi...

What is the current status of trial NCT00147056?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2012-08. Estimated completion is 2026-12.

What conditions does trial NCT00147056 study?

This clinical trial studies the following conditions: Brain Tumor.

What interventions are being tested in trial NCT00147056?

The interventions under investigation include: ExAblate transcranial system (DEVICE).

Who is sponsoring clinical trial NCT00147056?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00147056 being conducted?

This trial has 2 study locations across Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.